1962 Volume 15 Issue 6 Pages 254-257
Rifamycin SV (formerly rifomycin SV) is a new antibiotic discovered by Sensi et al1). It inhibits the growth of Gram-positive bacteria including Mycobacterium tuberculosis2). It was effective against experimental infections with Gram-positive bacteria3), and it had a very low toxicity4). It was found recently that this antibiotic is effective against infections in humans5–10).
It was reported that Staphylococcus aureus (209 P) rapidly developed resistance to this antibiotic and various strains resistant to other antibiotics were as equally susceptible to rifamycin SV as did that susceptible stain2). However, it is not known how develop strains resistant to other antibiotics resistance to rifamycin SV and, on the contrary, how behave rifamycin-resistant stains in developing resistances to other antibiotics. Resistance pattern to rifamycin SV is still unknown. The present paper deals with these subjects using Staphylococcus aureus 209 P as the test strain.